We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Activation of Nrf2 by Lithospermic Acid Ameliorates Myocardial Ischemia and Reperfusion Injury by Promoting Phosphorylation of AMP-Activated Protein Kinase α (AMPK α).
- Authors
Zhang, Min; Wei, Li; Xie, Saiyang; Xing, Yun; Shi, Wenke; Zeng, Xiaofeng; Chen, Si; Wang, Shasha; Deng, Wei; Tang, Qizhu
- Abstract
Background: As a plant-derived polycyclic phenolic carboxylic acid isolated from Salvia miltiorrhiza , lithospermic acid (LA) has been identified as the pharmacological management for neuroprotection and hepatoprotection. However, the role and mechanism of lithospermic acid in the pathological process of myocardial ischemia-reperfusion injury are not fully revealed. Methods: C57BL/6 mice were subjected to myocardial ischemia and reperfusion (MI/R) surgery and pretreated by LA (50 mg/kg, oral gavage) for six consecutive days before operation. The in vitro model of hypoxia reoxygenation (HR) was induced by hypoxia for 24 h and reoxygenation for 6 h in H9C2 cells, which were subsequently administrated with lithospermic acid (100 μM). Nrf2 siRNA and dorsomorphin (DM), an inhibitor of AMPKα, were used to explore the function of AMPK α /Nrf2 in LA-mediated effects. Results: LA pretreatment attenuates infarct area and decreases levels of TnT and CK-MB in plasm following MI/R surgery in mice. Echocardiography and hemodynamics indicate that LA suppresses MI/R-induced cardiac dysfunction. Moreover, LA ameliorates oxidative stress and cardiomyocytes apoptosis following MI/R operation or HR in vivo and in vitro. In terms of mechanism, LA selectively activates eNOS, simultaneously increases nuclear translocation and phosphorylation of Nrf2 and promotes Nrf2/HO-1 pathway in vivo and in vitro , while cardioprotection of LA is abolished by pharmacological inhibitor of AMPK or Nrf2 siRNA in H9C2 cells. Conclusion: LA protects against MI/R-induced cardiac injury by promoting eNOS and Nrf2/HO-1 signaling via phosphorylation of AMPK α.
- Subjects
REPERFUSION injury; MYOCARDIAL ischemia; NUCLEAR factor E2 related factor; MYOCARDIAL reperfusion; PROTEIN kinases; LABORATORY mice
- Publication
Frontiers in Pharmacology, 2021, Vol 12, p1
- ISSN
1663-9812
- Publication type
Article
- DOI
10.3389/fphar.2021.794982